Keith D. Mortman

Keith D. Mortman

Auto-generated profile, based on publicly available information

Keith D. Mortman

The George Washington University Hospital

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2014 in Lung Cancer
Verified
Journal Article
Closed access
DBDeborah Belchis
Deborah Belchis
MCMorgan Cowan
Morgan Cowan
KMKeith Mortman
Keith Mortman
BRB. Rezvani
B. Rezvani

1 November 2015 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
MSMatthew D. Skancke
Matthew D. Skancke
TATanya D. Auzenne
Tanya D. Auzenne
STSana O. Tabbara
Sana O. Tabbara
KMKeith D. Mortman
Keith D. Mortman

8 August 2018 in Journal of Medical Economics
Verified
Journal Article
Closed access
KMKeith D. Mortman
Keith D. Mortman
MCMitra Corral
Mitra Corral
XZXiaohong Zhang
Xiaohong Zhang
IBIndrias Berhane
Indrias Berhane
ISIreena M. Soleas
Ireena M. Soleas
NFNicole C. Ferko
Nicole C. Ferko
Aim: Progel Pleural Air Leak Sealant (Progel) is currently the only sealant approved by the FDA for the treatment of air leaks during lung surgery. This study was performed to determine whether Progel use improves hospital length of stay (LOS) and hospitalization costs compared with other synthetic/fibrin sealants in patients undergoing lung surgery. Methods: The US Premier hospital database was used to identify lung surgery discharges from January 1, 2010 to June 30, 2015. Eligible discharges were categorized as “Progel Sealant” or “other sealants” using hospital billing data. Propensity score matching (PSM) was performed to control for hospital and patient differences between study groups. Primary outcomes were hospital LOS and all-cause hospitalization costs. Clinical outcomes, hospital re-admissions, and sealant product use were also described. Results: After PSM, a total of 2,670 discharges were included in each study group; baseline characteristics were balanced between groups. The hospital LOS (mean days ± standard deviation, median) was significantly shorter for the Progel group (9.9 ± 9.6, 7.0) compared with the other sealants group (11.3 ± 12.8, 8.0; p < .001). Patients receiving Progel incurred significantly lower all-cause hospitalization costs ($31,954 ± $29,696, $23,904) compared with patients receiving other sealants ($36,147 ± $42,888, $24,702; p < .001). Limitations: It is not possible to say that sealant type alone was responsible for the findings of this study, and analysis was restricted to the data available in the Premier database. Conclusions: Among hospital discharges for lung surgery, Progel use was associated with significantly shorter hospital LOS and lower hospitalization costs compared with other synthetic/fibrin sealants, without compromising clinical outcomes.

1 May 2020 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
MNMichael A. Napolitano
Michael A. Napolitano
MSMatthew D. Skancke
Matthew D. Skancke
KMKeith D. Mortman
Keith D. Mortman
Objective: Surgery for early stage non–small cell lung cancer can be curative. A delay from diagnosis to surgery can lead to increased mortality. Our objective was to determine if referring patients to specialists before a thoracic surgeon caused a delay in definitive treatment. Materials and Methods: A retrospective review was conducted of patients who had surgery for non–small cell lung cancer by a single surgeon at our institution from 2013 to 2016. Patients were divided into 2 groups: those who saw a specialist before a thoracic surgeon and patients who were referred directly to a surgeon once the pulmonary nodule was identified on computed tomography (CT). The time from initial CT to resection was compared. Secondary analysis compared private insurance versus Medicare/Medicaid. Percentage of patients upstaged was compared. Results: There was no significant difference between groups when comparing time from CT to surgery (79.88 vs. 79.90 d; P=0.58). There was a significant decrease in time from CT to surgery for patients with private insurance compared with Medicare/Medicaid patients (66.05 vs. 86.99 d; P=0.03) and fewer private insurance patients were upstaged (22.9% vs. 31.8%; P=0.32). More patients who saw a different specialist first were upstaged compared with patients sent directly to thoracic surgery (32.6% vs. 22.2%; P=0.22). Conclusions: When comparing time from CT detection of a lung nodule to surgery, no significant difference was found between patients sent to nonthoracic specialists first and those referred directly to a thoracic surgeon. There was a significant decrease in time from CT to surgery for patients with private insurance compared with Medicare/Medicaid.

1 March 2016 in Chest
Verified
Journal Article
Closed access
JHJavi Hartenstine
Javi Hartenstine
HJHope Jackson
Hope Jackson
KMKeith Mortman
Keith Mortman

31 March 2021 in American Journal of Clinical Oncology
Verified
Journal Article
Closed access
KMKeith D. Mortman
Keith D. Mortman
JDJoseph Devlin
Joseph Devlin
BGBrian Ba Giang
Brian Ba Giang
RMRyan Bs Mortman
Ryan Bs Mortman
ASAndrew D. Sparks
Andrew D. Sparks
MNMichael A. Napolitano
Michael A. Napolitano
Objectives: Low-dose computed tomography (LDCT) screening is an important tool for reducing lung cancer mortality. This study describes a single center’s experience with LDCT and attempts to identify any barriers to compliance with standard guidelines. Materials and Methods: This is a retrospective review of a single university-based hospital system from 2015 to 2019. All individuals who met eligibility for lung cancer screening were entered into a database. The definition of adherence with the screening program was determined by the recommended timeline for the follow-up LDCT. Cohorts were split by adherence and demographics were compared. Results: A total of 203 LDCTs were performed in 121 patients who met eligibility for LDCT and had appropriate surveillance from 2015 to 2019. The average age was 64 years old. The overall adherence rate for prescribed LDCTs was 59.1%. Patients with Lung-RADS score 2 had 2.43 times higher odds of adherence relative to patients with Lung-RADS score 1 (odds ratio [OR]=2.43; 95% confidence interval [CI]: 1.23-4.83; P=0.011). African American patients had 42% lower odds of adherence relative to white patients (OR=0.58; 95% CI: 0.32-1.06; P=0.076). Patients with non–District of Columbia zip codes had 57% higher odds of adherence relative to those with District of Columbia zip codes, although this did not reach statistical significance (OR=1.57; 95% CI: 0.87-2.82; P=0.136). Conclusions: Despite the implementation of a multidisciplinary, academic LDCT screening program, overall adherence rate to prescribed follow-up scans was suboptimal. Socioeconomic disparities and African American race may negatively affect adherence to lung cancer screening LDCT guidelines. Patients with concerning findings on initial LDCT had a higher association of adherence to guidelines.